Education partnerships Opportunity to expand patient education and decision-support tools through collaborations with education platforms and patient resources, aligning with PreludeDx’s recent partnership with Learn Look Locate to enhance DCIS treatment understanding.

FDA and portfolio Leverage the FDA breakthrough designation for AidaBreast to position integrated diagnostic capabilities across early-stage breast cancer, creating cross-sell opportunities between DCISionRT and AidaBreast for comprehensive patient risk assessment.

Operational scale Expand capabilities and capacity planning with the newly appointed SVP of Operations to meet rising demand, enabling scalable lab operations and automation partnerships with CROs, diagnostic fulfillment networks, and cloud-based data platforms.

Technology stack Target IT and analytics vendors using PreludeDx’s diverse tech stack (AWS, Google Cloud, Salesforce, SAP, QuickBooks) to streamline labs, data management, CRM, and marketing automation—presenting cost-efficient, integrated solutions for biotech diagnostics.

Market expansion Capitalize on growth signals from executive appointments and portfolio expansion by offering managed services, regulatory consulting, and training for new tests to buyers in hospitals, cancer centers, and ambulatory clinics seeking precision diagnostics adoption.